Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose

BACKGROUND: To develop and validate a predictive nomogram for tumor residue 3–6 months after treatment based on postradiotherapy plasma Epstein–Barr virus (EBV) deoxyribonucleic acid (DNA), clinical stage, and radiotherapy (RT) dose in patients with stage II–IVA nasopharyngeal carcinoma (NPC) treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ying-Ying, Zhou, Jia-Yu, Zhan, Ze-Jiang, Ke, Liang-Ru, Xia, Wei-Xiong, Cao, Xun, Cai, Zhuo-Chen, Deng, Ying, Chen, Xi, Zhang, Lu-Lu, Huang, Hao-Yang, Guo, Xiang, Lv, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164328/
https://www.ncbi.nlm.nih.gov/pubmed/37149594
http://dx.doi.org/10.1186/s12885-023-10827-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164328/
https://www.ncbi.nlm.nih.gov/pubmed/37149594
http://dx.doi.org/10.1186/s12885-023-10827-0

Ejemplares similares